Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | DDX3X | O00571 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037544 | 0.83 | MEN1 (0.71) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL30020996 | 0.82 | MEN1 (0.75) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL239690 | 0.82 | MEN1 (0.75) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1999901 | 0.82 | AKR1C3 (0.63) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL18415225 | 0.81 | AKR1C3 (0.59) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL18236211 | 0.80 | ADORA2A (0.64) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1998435 | 0.79 | AKR1C3 (0.60) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL13058905 | 0.79 | AKR1C3 (0.79) | AKR1C3NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1998475 | 0.78 | AKR1C3 (0.59) | AKR1C3MEN1KMT2ADDX3XNTRK1 | |
| SCHEMBL18418447 | 0.78 | MEN1 (0.57) | AKR1C3NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| WO-2017015451-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | AKR1C3 200/4885NPC1 607/4885RAB9A 1332/4885 |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | AKR1C3 267/4885NPC1 472/4885RAB9A 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.